TAVO-PLUS-CD3

N/A

Report date: 2023/05/22 11:36:42

Base Information

Drug NameTAVO-PLUS-CD3
Drug Alias NameTAVO-PLUS-CD3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionInterleukin-12 stimulantsAnti-CD3
TargetsInterleukin-12T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncosec Medical
China Registration ClassN/A

Develop Information

Active CompaniesOncosec Medical
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A